Free access
1 November 1995

Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci

Abstract

Studies were conducted to validate the use of Enterococcus faecalis ATCC 51299 (which is vancomycin resistant and resistant to high levels of gentamicin and streptomycin) and E. faecalis ATCC 29212 (which is susceptible to vancomycin and against which gentamicin or streptomycin and cell wall-active agents have synergistic kill activity) as controls in an agar screening test for vancomycin resistance and high-level streptomycin and gentamicin resistance and a broth microdilution screening test for high-level streptomycin and gentamicin resistance. Both organisms performed as expected in these tests and will serve as appropriate controls. However, E. faecalis ATCC 29212 was occasionally noted to produce light growth on the vancomycin screening plate with certain lots of agar. Quality control ranges for disk diffusion tests with disks with large amounts of streptomycin (300 micrograms) and gentamicin (120 micrograms) were established for E. faecalis ATCC 29212; zone limits are 16 to 22 mm for gentamicin and 14 to 19 mm for streptomycin. No zones for inhibition were seen when E. faecalis ATCC 51299 was tested with these high-content disks.

Formats available

You can view the full content in the following formats:

Information & Contributors

Information

Published In

cover image Journal of Clinical Microbiology
Journal of Clinical Microbiology
Volume 33Number 11November 1995
Pages: 3019 - 3021
PubMed: 8576364

History

Published online: 1 November 1995

Permissions

Request permissions for this article.

Contributors

Authors

J M Swenson
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
N C Clark
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
D F Sahm
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
M J Ferraro
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
G Doern
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Hindler
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J H Jorgensen
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
M A Pfaller
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
L B Reller
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
M P Weinstein
Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

Metrics & Citations

Metrics

Note: There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.

Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

View Options

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy